17-beta-hydroxysteroid dehydrogenase deficiency screening: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{17-beta-hydroxysteroid dehydrogenase deficiency}} | {{17-beta-hydroxysteroid dehydrogenase deficiency}} | ||
{{CMG}}; {{AE}} {{Abdulkerim}} | |||
==Overview== | |||
==Screening== | |||
There is insufficient evidence to recommend routine screening for 17 alpha-hydroxylase deficiency. | There is insufficient evidence to recommend routine screening for 17 alpha-hydroxylase deficiency. | ||
==References== | ==References== |
Revision as of 07:27, 10 May 2022
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
17-beta-hydroxysteroid dehydrogenase deficiency screening On the Web |
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency screening |
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency screening |
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency screening |
17-beta-hydroxysteroid dehydrogenase deficiency screening in the news |
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency screening |
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Risk calculators and risk factors for 17-beta-hydroxysteroid dehydrogenase deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
Screening
There is insufficient evidence to recommend routine screening for 17 alpha-hydroxylase deficiency.